Related Experiment Video

Updated: Mar 13, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.5K

Functional and therapeutic relevance of hepatocyte growth factor/c-MET signaling in synovial sarcoma

Yoshinori Imura1,2, Takaaki Nakai1, Shutaro Yamada1

  • 1Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.

Cancer Science
|October 26, 2016
PubMed

Insights

Hepatocyte growth factor (HGF)/c-MET signaling drives aggressive synovial sarcoma (SS) by promoting growth and chemoresistance. Targeting this pathway with INC280 offers a promising therapeutic strategy for SS patients with poor prognoses.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Synovial sarcoma (SS) is an aggressive soft tissue sarcoma with limited treatment options.
  • Novel therapeutic strategies are urgently needed for SS patients with poor prognoses.

Purpose of the Study:

  • To investigate the role of hepatocyte growth factor (HGF)/c-MET signaling in SS.
  • To evaluate the therapeutic potential of targeting HGF/c-MET signaling in SS.

Main Methods:

  • Assessed HGF and c-MET expression and activation in SS cell lines.
  • Utilized INC280, a selective c-MET inhibitor, in vitro and in vivo.
  • Analyzed SS clinical samples for HGF and c-MET co-expression.

Main Results:

  • HGF/c-MET signaling was activated in aggressive SS cells (Yamato-SS), correlating with increased growth and chemoresistance.
  • INC280 inhibited growth, induced cell cycle arrest, and promoted apoptosis in c-MET-activated SS cells.
  • HGF and c-MET co-expression in SS patients predicted a poor prognosis.

Conclusions:

  • Autocrine HGF/c-MET activation drives an aggressive SS phenotype.
  • Targeting HGF/c-MET signaling with INC280 demonstrates significant antitumor effects in c-MET-activated SS.
  • HGF/c-MET expression status can serve as a biomarker for identifying SS patients who may benefit from c-MET inhibitors.
Keywords:
INC280Yamato-SSc-METhepatocyte growth factorsynovial sarcoma

More Related Videos

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.9K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

890

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.6K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.6K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
10.2K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.8K